Back to Search Start Over

Remote haemodynamic-guided heart failure management in France: Results from the CardioMEMS HF System Post-Market Study (COAST) French cohort.

Authors :
de Groote P
Thuny F
Blanchart K
Gueffet JP
Habib G
Salvat M
Leclercq C
Mouquet F
Roncalli J
Sebbag L
Cassagneau R
Peyrol M
Sabatier R
Gazzola C
Henderson J
Adamson PB
Roubille F
Source :
Archives of cardiovascular diseases [Arch Cardiovasc Dis] 2024 Nov; Vol. 117 (11), pp. 624-632. Date of Electronic Publication: 2024 Sep 12.
Publication Year :
2024

Abstract

Background: Previous studies have demonstrated the benefit of a haemodynamic-guided management strategy with the CardioMEMS™ HF System. No data from French patients have been published.<br />Aims: To analyse the feasibility, safety and clinical benefit of the CardioMEMS™ HF System in 103 French patients included in the CardioMEMS HF System Post-Market Study (COAST).<br />Methods: Prospective open-label cohort of New York Heart Association class III patients with at least one heart failure hospitalization in the 12 months before enrolment, regardless of left ventricular ejection fraction. The primary safety endpoints assessed the freedom from device/system-related complications and from pressure sensor failure at 2 years after implantation. The primary efficacy endpoint was evaluated comparing the rate of heart failure hospitalization during the year before and the year after implantation.<br />Results: At 2 years, there were no device/system-related complications or pressure sensor failures (P<0.0001). There were 179 heart failure hospitalizations in the year before implantation compared with 79 in the year after implantation (risk reduction 50.3%; rate ratio 0.50, 95% confidence interval 0.38-0.66; P<0.0001). During the 2 years of follow-up, pulmonary artery pressures were lowered significantly (mean pulmonary artery pressure -3.7±6.3mmHg; P<0.0001), with a significant improvement in functional class and quality of life.<br />Conclusions: In the French cohort of the COAST study, we have demonstrated that the CardioMEMS™ HF System is a reliable device, with no device/system-related complications or pressure sensor failures. Patients in this open-label cohort had a significant reduction in pulmonary artery pressures, with an improvement in New York Heart Association classification and quality of life, and a 50% reduction in the heart failure hospitalization rate in the year following implantation compared with the previous year.<br /> (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)

Details

Language :
English
ISSN :
1875-2128
Volume :
117
Issue :
11
Database :
MEDLINE
Journal :
Archives of cardiovascular diseases
Publication Type :
Academic Journal
Accession number :
39317620
Full Text :
https://doi.org/10.1016/j.acvd.2024.08.003